Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Intangibles (2016 - 2024)

ImmunityBio (IBRX) has disclosed Intangibles for 10 consecutive years, with $16.6 million as the latest value for Q1 2024.

  • On a quarterly basis, Intangibles changed N/A to $16.6 million in Q1 2024 year-over-year; TTM through Mar 2024 was $16.6 million, a N/A change, with the full-year FY2023 number at $17.1 million, changed N/A from a year prior.
  • Intangibles was $16.6 million for Q1 2024 at ImmunityBio, down from $17.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $22.3 million in Q1 2022 to a low of $1.4 million in Q4 2021.
  • A 5-year average of $10.5 million and a median of $9.0 million in 2020 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: decreased 2.94% in 2021, then skyrocketed 1454.17% in 2022.
  • ImmunityBio's Intangibles stood at $1.5 million in 2020, then fell by 2.94% to $1.4 million in 2021, then surged by 1341.62% to $20.5 million in 2022, then fell by 16.5% to $17.1 million in 2023, then decreased by 3.05% to $16.6 million in 2024.
  • Per Business Quant, the three most recent readings for IBRX's Intangibles are $16.6 million (Q1 2024), $17.1 million (Q4 2023), and $20.5 million (Q3 2022).